Effectiveness of biweekly low-dosage peginterferon treatment on the improvement

StephenW

Source: Hepatol Res  |  Posted 6 days agohttp://www.docguide.com/effectiveness-biweekly-low-dosage-peginterferon-treatment-improvement-serum-alanine-aminotransferase

Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels; Kajiwara E, Ooho A, Yamashita N; Hepatology Research (Dec 2011)

Aim:  The purpose of this clinical study was to determine the effect of a biweekly low-dosage peginterferon α-2a treatment program on serum alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels. Methods:  Fifty-five patients participated in the study. The inclusion criteria included chronic genotype 1b hepatitis C virus (HCV) infection, liver cirrhosis, or the absence of cirrhosis in subjects 65 years old or above, and interferon therapy naivety or a lack of sustained response to therapy with interferon-plus-ribavirin or peginterferon-plus-ribavirin. Patients were divided into naïve, relapser, and non-responder groups. The median age of the patients was 70 years, and 73% of patients had cirrhosis. All patients were treated with peginterferon α-2a at 90 µg biweekly. Results:  The rates of normalization (≤30 IU/l) of ALT levels at week 24 in the relapser group and the ≥2 log(10)  HCV RNA decline group were high (74% and 68%, respectively). However, the ALT and AFP levels decreased significantly in each group, including the non-responder group. The ALT levels decreased significantly even in patients in whom the HCV RNA levels did not decrease. Furthermore, the AFP levels decreased significantly in the patients showing no decline in the ALT and HCV RNA levels. Only three patients discontinued treatment within 48 weeks due to adverse events, and more than 70% of the patients experienced no subjective symptoms during treatment. Conclusion:  A biweekly low-dosage peginterferon α-2a therapy is effective for reducing the serum levels of ALT and AFP and may reduce hepatocarcinogenesis in patients with liver cirrhosis and in the elderly individuals.

StephenW

来源：肝胆病研究|发表于6天前
血清谷丙转氨酶和α-甲胎蛋白水平的提高双周低剂量聚乙二醇干扰素治疗的有效性;梶原E，Ooho一个，山下ñ;肝病研究（2011年12月）
打印此|期刊|获取全文

目的：本临床研究的目的是要确定每两周一次低剂量聚乙二醇干扰素α- 2a的血清谷丙转氨酶（ALT）和α-甲胎蛋白（AFP）水平的治疗方案的效果。方法：55例患者参与了这项研究。入选标准包括慢性1b型丙型肝炎病毒（HCV）感染，肝硬化，肝硬化的情况下在65岁或以上的科目，和干扰素治疗幼稚或干扰素加病毒唑缺乏持续治疗反应或聚乙二醇干扰素加利巴韦林。患者分为天真，relapser和非应答组。病人的平均年龄为70岁，73％的患者有肝硬化。所有患者均采用聚乙二醇干扰素α- 2a的双周在90微克。结果：利率正常化relapser组和≥2日志（10）丙型肝炎病毒RNA下降组在第24周时，ALT水平（≤30 IU / L），高（分别为74％和68％）。然而，ALT和AFP水平在各组显着下降，包括非应答组。 ALT水平下降显著，甚至在患者HCV RNA水平在其中并没有减少。此外，AFP水平显着降低患者ALT和HCV RNA水平没有下降。只有三例患者的48个星期内，因不良事件停止治疗，超过70％的患者在治疗过程中经历没有主观症状。结论：每两周一次低剂量聚乙二醇干扰素α- 2a的治疗是有效地降低血清ALT和AFP水平，并可能降低肝硬化和肝癌在老人的个人。